CURASEN THERAPEUTICS
CuraSen Therapeutics is a biopharmaceutical company that develops orphan drugs to treat neurodegenerative diseases, including Parkinson's disease and Alzheimer's disease.
CURASEN THERAPEUTICS
Industry:
Biotechnology Medical Device Therapeutics
Founded:
2016-01-01
Address:
San Carlos, California, United States
Country:
United States
Website Url:
http://www.curasen.com
Total Employee:
11+
Status:
Active
Contact:
+1 650 475 2842
Email Addresses:
[email protected]
Total Funding:
72.5 M USD
Technology used in webpage:
SPF Microsoft Exchange Online Office 365 Mail Microsoft Azure DNS Google Google Cloud Google Cloud Iowa
Similar Organizations
Accent Therapeutics
Accent Therapeutics is a biopharmaceutical company.
Cygnal Therapeutics
Cygnal Therapeutics is a biotechnology company
Emendo Biotherapeutics
Emendo Biotherapeutics is a biotechnology company
ExCellThera
ExCellThera is an advanced clinical stage biotechnology company.
Libra Therapeutics
Libra Therapeutics is a biotechnology company.
MOMA Therapeutics
MOMA Therapeutics operates as a biotechnology company.
Primmune Therapeutics
Primmune Therapeutics is a Biotechnology company.
Terray Therapeutics
Terray Therapeutics is a biotechnology company that propels drug discovery into the information age.
Current Advisors List
Current Employees Featured
Founder
Investors List
Pappas Capital
Pappas Capital investment in Series A - CuraSen Therapeutics
Chiesi Ventures
Chiesi Ventures investment in Series A - CuraSen Therapeutics
Johnson & Johnson Innovation โ JJDC
Johnson & Johnson Innovation โ JJDC investment in Series A - CuraSen Therapeutics
Tekla Capital Management
Tekla Capital Management investment in Series A - CuraSen Therapeutics
New Leaf Venture Partners
New Leaf Venture Partners investment in Series A - CuraSen Therapeutics
Longitude Capital
Longitude Capital investment in Series A - CuraSen Therapeutics
Alta Partners
Alta Partners investment in Series A - CuraSen Therapeutics
Official Site Inspections
http://www.curasen.com Semrush global rank: 8.64 M Semrush visits lastest month: 274
- Host name: 95.6.226.35.bc.googleusercontent.com
- IP address: 35.226.6.95
- Location: United States
- Latitude: 38.6583
- Longitude: -77.2481
- Timezone: America/New_York
More informations about "CuraSen Therapeutics"
About - CuraSen
CuraSen Therapeutics, Inc. is a privately funded biopharmaceutical company pursuing development of novel treatments for psychiatric and โฆSee details»
CuraSen - 2025 Company Profile, Funding & Competitors - Tracxn
CuraSen is a series B company based in San Mateo (United States), founded in 2013 by Kathleen Sereda Glaub, Anthony Ford, Mehrdad Shamloo and Robert Booth. It operates as a Provider โฆSee details»
CuraSen Therapeutics, Inc. - Drug pipelines, Patents, Clinical trials ...
Explore CuraSen Therapeutics, Inc. with its drug pipeline, therapeutic area, technology platform, 8 clinical trials, 18 news, and 3 literature, Disease Domain:Nervous ...See details»
CuraSen Therapeutics - Pappas Capital
CuraSen Therapeutics is focused on the discovery and development of therapies to treat neurodegenerative diseases, including Parkinsonโs Disease, Alzheimerโs Disease and less โฆSee details»
CuraSen Therapeutics, Inc. - LinkedIn
CuraSen Therapeutics, Inc. is a privately funded biopharmaceutical company pursuing development of novel treatments for neurodegenerative diseases, including Parkinsonโs โฆSee details»
CuraSen Therapeutics: Revenue, Worth, Valuation & Competitors โฆ
CuraSen Therapeutics is a Biotech related company founded in 2017 and based in San Mateo with an estimated revenue of $3.3M, and 21 employees. It has 10 competitors including โฆSee details»
CuraSen 2025 Company Profile: Valuation, Funding & Investors
Information on valuation, funding, cap tables, investors, and executives for CuraSen. Use the PitchBook Platform to explore the full profile.See details»
Home | CuraSen
Think, Again© 2025 by CuraSen Therapeutics, Inc.See details»
CuraSen Therapeutics - Crunchbase Company Profile & Funding
CuraSen Therapeutics is a biopharmaceutical company that develops orphan drugs to treat neurodegenerative diseases, including Parkinson's disease, and Alzheimer's disease.See details»
CuraSen Therapeutics Appoints Kathleen Sereda Glaub as CEO
Oct 20, 2024 The appointment of Kathleen Sereda Glaub as CEO brings a wealth of strategic and leadership experience, positioning CuraSen for success in advancing its clinical programs. โฆSee details»
CuraSen Therapeutics Appoints Kathleen Sereda Glaub Chief
Oct 15, 2024 Expands Adrenergic Pipeline to Address Neurogenic Orthostatic Hypotension and Major Depressive Disorder in Older Adults SAN CARLOS, Calif.-- (BUSINESS WIRE)- โฆSee details»
CuraSen Therapeutics - News, Locations, Executives and โฆ
Usearch discovered 1 location for CuraSen Therapeutics including locations in San Carlos · California. CuraSen Therapeutics is headquartered in 930 Brittan Ave. Usearch has identified โฆSee details»
Curasen Therapeutics Inc. | Alzheimer's Drug Discovery Foundation
Sep 1, 2023 At CuraSen, we contend that these failures to treat complex brain diseases derive from well-intentioned, but misplaced focus on non-causal pathologic substrates, single genes, โฆSee details»
Leadership - CuraSen
Prior to CuraSen, Dr. Ford co-founded Afferent Pharmaceuticals, and as chief scientific officer led the discovery and development of first-in-class P2X3 antagonists, including AF-219/MK-7264 โฆSee details»
CuraSen - VentureRadar
"CuraSen Therapeutics, Inc. is developing drugs targeting a novel mechanism in the brain to restore function, improve symptoms and modify disease in a range of neurodegenerative โฆSee details»
CuraSen - 2025 Funding Rounds & List of Investors - Tracxn
Jun 21, 2025 CuraSen has raised a total funding of $59.8M over 3 rounds from 7 investors. Investors include Alta Partners, New Leaf Venture Partners and 5 others. Their latest funding โฆSee details»
Pipeline - CuraSen
Pipeline© 2025 by CuraSen Therapeutics, Inc.See details»
CuraCN - Drug Targets, Indications, Patents - Synapse
CuraCN: a ฮฒ2-adrenergic receptor agonists Drug, Initially developed by CuraSen Therapeutics, Inc., Now, its global highest R&D status is Phase 2, Mechanism: ฮฒ2-adrenergic receptor โฆSee details»
CuraSen Therapeutics, Inc. โ Funding, Valuation, Investors, News
Oct 16, 2023 CuraSen Therapeutics, Inc. is a privately funded biopharmaceutical company pursuing development of novel treatments for neurodegenerative diseases, including โฆSee details»
Science - CuraSen
CuraSenโs approach is focused on restoring the lost adrenergic impact of adequate noradrenaline stimulus by directly activating specific targets, such as the ฮฒ2 and ฮฑ1A adrenoceptors, for โฆSee details»